Výsledky vyhledávání - "Hyung-Suk Hur"

Supplementary figure 2 from GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands

Supplementary Figure 2. The EGFR-GC1118 interaction is not disrupted by excess amounts of high- or low-affinity EGFR ligands. The indicated colorectal cancer cell lines were pre-incubated with 0.1 ug/ml of cetuximab or GC1118 for 2 h prior to the add

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::725f884ad46d30da06419018eeec1d81
https://doi.org/10.1158/1535-7163.22503043

Zobrazit plný text záznamu

Supplementary figure 1 from GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands

Supplementary Figure 1. Kinetic binding interactions between GC1118 and EGFR as analyzed by SPR. SPR sensorgrams were obtained from injections of (A) GC1118 or (B) cetuximab over an EGFR-immobilized surface at a flow rate of 30 Âµl/min. The results

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08c649a0a3bacb6dfcc106d8d9e853e5
https://doi.org/10.1158/1535-7163.22503046

Zobrazit plný text záznamu

Supplementary table 1 from GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands

Supplementary Table 1. X-ray data collection and refinement statistics.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b7dae88c660f0113a5814ad11b8dd2f
https://doi.org/10.1158/1535-7163.22503037.v1

Zobrazit plný text záznamu

Supplementary method from GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands

Surface plasmon resonance (SPR)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80b986e8555bae1ac03b9cf184edfa9b
https://doi.org/10.1158/1535-7163.22503040

Zobrazit plný text záznamu

GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands

Publikováno v: Molecular Cancer Therapeutics. 15:251-263

The EGFR-targeted monoclonal antibodies are a valid therapeutic strategy for patients with metastatic colorectal cancer (mCRC). However, only a small subset of mCRC patients has therapeutic benefits and there are high demands for EGFR therapeutics wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7d320e3c8310b2bba6b7c84a297fe0e
https://doi.org/10.1158/1535-7163.mct-15-0679

Zobrazit plný text záznamu

Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab

Publikováno v: BioMed Central Ltd
Molecular Cancer

Background: Inhibition of the activated epidermal growth factor receptor (EGFR) with either enzymatic kinase inhibitors or anti-EGFR antibodies such as cetuximab, is an effective modality of treatment for multiple human cancers. Enzymatic EGFR inhibi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30ecde171df1d917eea86a882e7c8f76
https://doi.org/10.1186/1476-4598-13-141

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání